Juan Jose Perez Ruixo (Juan-Jose Perez-Ruixo, Carlos Perez-Ruixo, Juan-José Pérez-Ruixo, Juan Jose Pérez-Ruixo, Juan José Perez-Ruixo, Juan José Pérez-Ruixo, Juan José Perez Ruixo)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 27

Top Venues

Clinical pharmacokinetics

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Cancer chemotherapy and pharmacology

Janssen Research and Development Beerse

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Janssen Research and Development Beerse Dec 14 2014

Belgium

Senior Director :: Clinical Pharmacology & Pharmacometrics

Publications

Alex Yu, Anasuya Hazra, James Juhui Jiao, Peter Hellemans, Anna Mitselos, Hui Tian, Juan Jose Perez Ruixo, Nahor Haddish-Berhane, Daniele Ouellet, Alberto Russu
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation. Clinical pharmacokinetics 63 (4) (2024)
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan Jose Perez Ruixo
Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice. CPT: pharmacometrics & systems pharmacology (2024)
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan Jose Perez Ruixo
Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Alex Yu, Anasuya Hazra, James Juhui Jiao, Peter Hellemans, Anna Mitselos, Hui Tian, Juan Jose Perez Ruixo, Nahor Haddish-Berhane, Daniele Ouellet, Alberto Russu
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation. Clinical pharmacokinetics 63 (4) (2024)
Alex Yu, Anasuya Hazra, James Juhui Jiao, Peter Hellemans, Anna Mitselos, Hui Tian, Juan Jose Perez Ruixo, Nahor Haddish-Berhane, Daniele Ouellet, Alberto Russu
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation. Clinical pharmacokinetics (2024)
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan Jose Perez Ruixo
Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Alex Yu, Anasuya Hazra, James Juhui Jiao, Peter Hellemans, Anna Mitselos, Hui Tian, Juan Jose Perez Ruixo, Nahor Haddish-Berhane, Daniele Ouellet, Alberto Russu
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation. Clinical pharmacokinetics 63 (4) (2024)
Alex Yu, Anasuya Hazra, James Juhui Jiao, Peter Hellemans, Anna Mitselos, Hui Tian, Juan Jose Perez Ruixo, Nahor Haddish-Berhane, Daniele Ouellet, Alberto Russu
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation. Clinical pharmacokinetics 63 (4) (2024)
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan Jose Perez Ruixo
Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan Jose Perez Ruixo
Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan Jose Perez Ruixo
Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice. CPT: pharmacometrics & systems pharmacology 13 (5) (2024)
Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff, Karin Hardt, Javier Ruiz-Guiñazú, Juan Jose Perez Ruixo
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans. CPT: pharmacometrics & systems pharmacology (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Terra M Kruger, Belén Valenzuela, Charles D Thompson, Sivi Ouwerkerk-Mahadevan, Juan Jose Perez Ruixo
Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Clinical pharmacokinetics (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Anna Dari, Laura Solforosi, Ramon Roozendaal, Richard M W Hoetelmans, Juan Jose Perez Ruixo, Muriel Boulton
Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates. The Journal of pharmacology and experimental therapeutics (2023)
Anne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Avadhani, Anne O'Hagan, Lilian Y Li, Daniele Ouellet, Juan Jose Perez Ruixo
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. Cancer chemotherapy and pharmacology 89 (2) (2022)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics (2022)
Per Olsson Gisleskog, Belén Valenzuela, Tatiana Scherz, Michel Burcklen, Juan Jose Perez Ruixo, Italo Poggesi
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. Clinical pharmacokinetics 60 (9) (2021)
Anne-Gaëlle Dosne, Elodie Valade, Kim Stuyckens, Peter De Porre, Anjali Avadhani, Anne O'Hagan, Lilian Y Li, Daniele Ouellet, Ruben Faelens, Quentin Leirens, Italo Poggesi, Juan Jose Perez Ruixo
Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer. CPT: pharmacometrics & systems pharmacology (2021)
Belén Valenzuela, Juan Jose Perez Ruixo, Quentin Leirens, Sivi Ouwerkerk-Mahadevan, Italo Poggesi
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. Clinical pharmacokinetics 60 (9) (2021)
Lene Nygaard Axelsen, Italo Poggesi, Freya Rasschaert, Juan Jose Perez Ruixo, Shirin Bruderer
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. British journal of clinical pharmacology 87 (1) (2020)
Per Olsson Gisleskog, Juan Jose Perez Ruixo, Åke Westin, Anna C Hansson, Paul A Soons
Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration. Clinical pharmacokinetics 60 (4) (2020)
Juan Jose Perez Ruixo, Oliver Ackaert, Daniele Ouellet, Caly Chien, Hiroji Uemura, David Olmos, Paul Mainwaring, Ji Youl Lee, Margaret K Yu, Matthew R Smith, Eric J Small
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (17) (2020)
Elodie Valade, Anne-Gaëlle Dosne, Hong Xie, Robert B Kleiman, Lilian Y Li, Juan Jose Perez Ruixo, Daniele Ouellet
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors. Cancer chemotherapy and pharmacology 84 (3) (2019)

Juan Jose Perez Ruixo.css-eqlu8i{font-size:small;padding-left:4px;} (Juan-Jose Perez-Ruixo, Carlos Perez-Ruixo, Juan-José Pérez-Ruixo, Juan Jose Pérez-Ruixo, Juan José Perez-Ruixo, Juan José Pérez-Ruixo, Juan José Perez Ruixo)

Publication Activity (10 Years)

Top Topics

Top Venues

Juan Jose Perez Ruixo (Juan-Jose Perez-Ruixo, Carlos Perez-Ruixo, Juan-José Pérez-Ruixo, Juan Jose Pérez-Ruixo, Juan José Perez-Ruixo, Juan José Pérez-Ruixo, Juan José Perez Ruixo)